Servier Hellas

Servier Hellas company information, Employees & Contact Information

Explore related pages

Related company profiles:

Η Servier είναι ένας διεθνής φαρμακευτικός όμιλος, ο οποίος διοικείται από ένα ανεξάρτητο Ίδρυμα, δεσμευμένος να έχει ουσιαστικό κοινωνικό αντίκτυπο, για τους ασθενείς και να συνεισφέρει στην οικοδόμηση ενός βιώσιμου κόσμου. Το μοναδικό μοντέλο διακυβέρνησης του Ομίλου διασφαλίζει την ανεξαρτησία του και ενισχύει την μακροπρόθεσμη καινοτομία, καθώς το 100% των κερδών του επανεπενδύονται στην ανάπτυξη της εταιρείας. Ως παγκόσμιος ηγέτης στον τομέα των καρδιομεταβολικών και φλεβικών παθήσεων, η Servier προωθεί μετασχηματιστική καινοτομία στις χρόνιες παθήσεις μέσω μιας ολιστικής προσέγγισης, δίνοντας προτεραιότητα στη συμμόρφωση των ασθενών σε παγκόσμιο επίπεδο. Φιλοδοξία της Servier είναι να αναδειχθεί σε κορυφαίο παράγοντα στον τομέα των σπάνιων μορφών καρκίνου, γι’ αυτό και ο Όμιλος επενδύει δυναμικά στην ογκολογία, διαθέτοντας σχεδόν το 70% του προϋπολογισμού της Έρευνας & Ανάπτυξης σε αυτόν τον τομέα. Αξιοποιώντας την Ιατρική Ακριβείας, η Servier αναπτύσσει στοχεύουσες και πιο αποτελεσματικές θεραπείες. Ενισχυμένη από την επιτυχία της στην ογκολογία, η Servier έχει επεκταθεί στον τομέα της Νευρολογίας, έναν βασικό μοχλό μελλοντικής ανάπτυξης. Ο Όμιλος επικεντρώνεται σε έναν επιλεγμένο αριθμό νευροεκφυλιστικών νόσων, όπου ο ακριβής χαρακτηρισμός των ασθενών επιτρέπει στοχευμένες θεραπευτικές παρεμβάσεις μέσω της Ιατρικής Ακριβείας. Για την περαιτέρω ενίσχυση της πρόσβασης σε ποιοτική και προσιτή φροντίδα, ο Όμιλος προσφέρει επίσης ποιοτικά γενόσημα φάρμακα βασιζόμενος σε ισχυρές εταιρείες με έδρα τη Γαλλία, την Ανατολική Ευρώπη, και τη Βραζιλία.

Company Details

Employees
53
Address
Φραγκοκκλησιάς 7, Μαρούσι,αττική 15125,greece
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
servier.gr
HQ
Μαρούσι, Αττική
Looking for a particular Servier Hellas employee's phone or email?

Servier Hellas Questions

News

European Commission Approves Servier's VORANIGO® (vorasidenib) as the First Targeted Therapy for Grade 2 IDH-Mutant Glioma in the EU - PR Newswire

European Commission Approves Servier's VORANIGO® (vorasidenib) as the First Targeted Therapy for Grade 2 IDH-Mutant Glioma in the EU PR Newswire

Servier’s Therapy for IDH Mutant Glioma was Nominated for 2025 Prix Galien USA Award - Oncodaily

Servier’s Therapy for IDH Mutant Glioma was Nominated for 2025 Prix Galien USA Award Oncodaily

JPM25: As Servier cements oncology bona fides, US chief stresses importance of 'staying authentic' - Fierce Pharma

JPM25: As Servier cements oncology bona fides, US chief stresses importance of 'staying authentic' Fierce Pharma

Servier joins the menin club | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Servier joins the menin club | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Servier to Present Data on IDH-mutant Glioma at the 2024 Society for Neuro-Oncology (SNO) Congress - PR Newswire

Servier to Present Data on IDH-mutant Glioma at the 2024 Society for Neuro-Oncology (SNO) Congress PR Newswire

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy - Servier

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy Servier

FDA approves Servier's VORANIGO for IGrade 2 glioma - Pharmaceutical Technology

FDA approves Servier's VORANIGO for IGrade 2 glioma Pharmaceutical Technology

Servier Gets FDA Approval for First Targeted Therapy for Grade 2 IDH-Mutant Glioma - BioSpace

Servier Gets FDA Approval for First Targeted Therapy for Grade 2 IDH-Mutant Glioma BioSpace

US FDA approves Servier's brain tumor treatment - Reuters

US FDA approves Servier's brain tumor treatment Reuters

Marking One Year of Progress in IDH-Mutant Glioma Treatment – Servier Pharmaceuticals - Oncodaily

Marking One Year of Progress in IDH-Mutant Glioma Treatment – Servier Pharmaceuticals Oncodaily

Servier snags FDA approval for Voranigo, the first targeted therapy for a common type of brain tumor - Fierce Pharma

Servier snags FDA approval for Voranigo, the first targeted therapy for a common type of brain tumor Fierce Pharma

Learn more about our development portfolio - Servier

Learn more about our development portfolio Servier

EC approves Servier’s Voranigo to treat IDH-mutant glioma - Pharmaceutical Technology

EC approves Servier’s Voranigo to treat IDH-mutant glioma Pharmaceutical Technology

Servier's VORANIGO® (vorasidenib) Tablets Receives FDA Approval as First Targeted Therapy for Grade 2 IDH-mutant Glioma - PR Newswire

Servier's VORANIGO® (vorasidenib) Tablets Receives FDA Approval as First Targeted Therapy for Grade 2 IDH-mutant Glioma PR Newswire

See our bases throughout the world - Servier

See our bases throughout the world Servier

Potential Breakthrough for Glioma: Servier’s Therapy Nears EMA Approval - Servier Pharmaceuticals - Oncodaily

Potential Breakthrough for Glioma: Servier’s Therapy Nears EMA Approval - Servier Pharmaceuticals Oncodaily

Servier's Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI) - PR Newswire

Servier's Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI) PR Newswire

The Group in figures - Servier

The Group in figures Servier

Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma - PR Newswire

Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma PR Newswire

Our ambition for 2030 - Servier

Our ambition for 2030 Servier

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma - The New England Journal of Medicine

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma The New England Journal of Medicine

Our commitment to oncology - Servier

Our commitment to oncology Servier

Glioma: a rare, aggressive brain tumor - Servier

Glioma: a rare, aggressive brain tumor Servier

Big Servier Acquisition Pays Off as FDA Approves Drug for Two Types of Rare Brain Cancer - MedCity News

Big Servier Acquisition Pays Off as FDA Approves Drug for Two Types of Rare Brain Cancer MedCity News

Servier leverages Aitia's digital twins to drive glioma drug development - FirstWord Pharma

Servier leverages Aitia's digital twins to drive glioma drug development FirstWord Pharma

Servier serves up phase 3 brain tumor win at interim analysis, validating $1.8B buyout of Agios unit - Fierce Biotech

Servier serves up phase 3 brain tumor win at interim analysis, validating $1.8B buyout of Agios unit Fierce Biotech

ASCO: At long last, Servier finds a survival benefit in difficult brain cancer - Fierce Biotech

ASCO: At long last, Servier finds a survival benefit in difficult brain cancer Fierce Biotech

Servier completes acquisition of Agios Pharmaceuticals’ oncology business - Servier

Servier completes acquisition of Agios Pharmaceuticals’ oncology business Servier

Servier's $1.8 Billion Acquisition Pays Off: FDA Approves First-In-Class Treatment for Two Types of Rare Brain Cancer - geneonline.com

Servier's $1.8 Billion Acquisition Pays Off: FDA Approves First-In-Class Treatment for Two Types of Rare Brain Cancer geneonline.com

Servier to Acquire Agios Pharmaceuticals' Oncology Business - PR Newswire

Servier to Acquire Agios Pharmaceuticals' Oncology Business PR Newswire

FDA approves Servier’s Voranigo to treat brain cancer in adult and paediatric patients - PMLiVE

FDA approves Servier’s Voranigo to treat brain cancer in adult and paediatric patients PMLiVE

Servier's beefing up in oncology through dealmaking and Tibsovo wins—and it's not done yet, U.S. CEO says - Fierce Pharma

Servier's beefing up in oncology through dealmaking and Tibsovo wins—and it's not done yet, U.S. CEO says Fierce Pharma

Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology Annual Meeting - Allogene

Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology Annual Meeting Allogene

Treatment Breakthrough for an Intractable Brain Cancer - The Wall Street Journal

Treatment Breakthrough for an Intractable Brain Cancer The Wall Street Journal

ASCO 2023 – Servier’s Indigo win comes with liver tox | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASCO 2023 – Servier’s Indigo win comes with liver tox | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant diffuse glioma - PR Newswire

FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant diffuse glioma PR Newswire

All our latest news - Servier

All our latest news Servier

Servier - Massachusetts Biotechnology Council

Servier Massachusetts Biotechnology Council

FDA Approves IDH1/2+ Companion Diagnostic for Vorasidenib in Grade 2 Astrocytoma or Oligodendroglioma - OncLive

FDA Approves IDH1/2+ Companion Diagnostic for Vorasidenib in Grade 2 Astrocytoma or Oligodendroglioma OncLive

Servier Expands Cancer Focus with $2 Billion Buy of Agios’ Oncology Business - BioSpace

Servier Expands Cancer Focus with $2 Billion Buy of Agios’ Oncology Business BioSpace

Agios offloads oncology unit to Servier in $1.8B deal, zeroes in on genetically defined diseases - Fierce Biotech

Agios offloads oncology unit to Servier in $1.8B deal, zeroes in on genetically defined diseases Fierce Biotech

Health Canada Approves First and Only Oral Targeted Treatment for Brain Cancer - PR Newswire Canada

Health Canada Approves First and Only Oral Targeted Treatment for Brain Cancer PR Newswire Canada

Top Servier Hellas Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant